Opendata, web and dolomites

QuickMIC

QuickMIC™ - an ultra-rapid diagnostic system for Antibiotic Susceptibility Testing (AST)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 QuickMIC project word cloud

Explore the words cloud of the QuickMIC project. It provides you a very rough idea of what is the project "QuickMIC" about.

gradientech    patient    reduce    hours    time    worldwide    resistance    misuse    innovation    treatment    tested    treating    escalating    infection    million    commercialisation    image    treat    diagnosis    successful    diagnostic    spectrum    susceptibility    continuous    combining    amr    contribution    improvement    globally    rapid    usually    guide    price    detection    patented    disease    market    ivd    plan    2019    bacterial    death    antimicrobial    empirically    ultra    blood    appropriate    besides    standard    trade    empirical    antibiotics    ed    doctors    quickmic    fighting    competitors    sepsis    ce    microfluidics    patients    unsuccessful    continued    competitiveness    golden    quicker    tool    significantly    marking    approx    survive    business    additionally    commercializing    fastest    effort    clinical    decrease    alternative    survival    direct    48    more    contributes    platform    ast    people    unmet    rates    antibiotic    samples   

Project "QuickMIC" data sheet

The following table provides information about the project.

Coordinator
GRADIENTECH AB 

Organization address
address: UPPSALA SCIENCE PARK
city: UPPSALA
postcode: 75183
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://gradientech.se/funding-horizon-2020-sme-instrument/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRADIENTECH AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to bring QuickMIC™, an ultra-rapid diagnostic tool for Antibiotic Susceptibility Testing (AST) to the market and clinical practice. AST is usually carried out to determine which antibiotic will be the most appropriate in treating a bacterial infection in a particular patient. Sepsis is the major cause of death as a result of an infection today. It affects approx. 30 million of people every year worldwide. About 20 % of the patients do not survive the disease. Currently, it can take up to 48 hours for the current golden standard AST method to produce reliable diagnostic results. Therefore, doctors empirically treat sepsis patients with wide-spectrum antibiotics while the blood samples are being tested. The globally escalating antimicrobial resistance (AMR) has resulted in empirical treatment being unsuccessful more and more often. Misuse of antibiotics additionally contributes to increasing resistance. The improvement of survival rates in sepsis and the decrease in AMR will only be possible with access to a quicker AST tool. To address this unmet clinical need, Gradientech is developing an ultra-rapid AST system, QuickMIC™, based on a patented technology platform. By combining i) advanced microfluidics and ii) continuous image detection and analysis, QuickMIC™ can reduce the time of an AST to two hours. Besides being the fastest AST under development, QuickMIC™ is also a low-price alternative compared to its direct competitors. By commercializing QuickMIC™, Gradientech will make an important contribution to fighting AMR in Europe. Moreover, we will significantly improve the diagnosis and treatment of sepsis. A continued development of QuickMIC™ will result in a CE-IVD marking by early 2019. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation activities. If successful, the overall innovation effort will take Gradientech to a new level of competitiveness and growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUICKMIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUICKMIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More